Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 11, 2026, 4:05 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 255 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Usual Interstitial Pneumonia Clear all
Completed No phase listed Observational

Quality of Life in IPF - Patient and Physician Perceptions

NCT04148157
View directory record Official record
Conditions
Idiopathic Pulmonary Fibrosis
Interventions
Not listed
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Dec 10, 2024 · Synced Sep 11, 2026, 4:05 PM EDT
Completed Phase 2 Interventional Results available

Safety, Tolerability, and Efficacy of MN-001 (Tipelukast) in Patients With Idiopathic Pulmonary Fibrosis

NCT02503657
View directory record Official record
Conditions
Idiopathic Pulmonary Fibrosis, IPF
Interventions
MN-001, Placebo
Drug
Lead sponsor
MediciNova
Industry
Eligibility
21 Years to 80 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
1
States / cities
Hershey, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 22, 2026 · Synced Sep 11, 2026, 4:05 PM EDT
Completed Phase 2 Interventional

Biomarker Modulation and the Inhibition of NKT1 Cells by Oral GRI-0621 in Patients With IPF

NCT06331624
View directory record Official record
Conditions
Idiopathic Pulmonary Fibrosis, IPF
Interventions
Tazarotene (GRI-0621), Placebo
Drug
Lead sponsor
GRI Bio Operations, Inc.
Industry
Eligibility
40 Years to 85 Years
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
5
States / cities
Newport Beach, California • Jacksonville, Florida • The Bronx, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Oct 29, 2025 · Synced Sep 11, 2026, 4:05 PM EDT
Terminated Phase 3 Interventional Results available

Zephyrus I: Evaluation of Efficacy and Safety of Pamrevlumab in Participants With Idiopathic Pulmonary Fibrosis (IPF)

NCT03955146
View directory record Official record
Conditions
Idiopathic Pulmonary Fibrosis
Interventions
Pamrevlumab, Placebo
Drug
Lead sponsor
Kyntra Bio
Industry
Eligibility
40 Years to 85 Years
Enrollment
393 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
60
States / cities
Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 50 more
Source: ClinicalTrials.gov public record
Updated Sep 18, 2024 · Synced Sep 11, 2026, 4:05 PM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy of a Lysophosphatidic Acid Receptor Antagonist in Idiopathic Pulmonary Fibrosis

NCT01766817
View directory record Official record
Conditions
Idiopathic Pulmonary Fibrosis
Interventions
BMS-986020, Placebo matching with BMS-986020
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
40 Years to 90 Years
Enrollment
325 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
48
States / cities
Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 42 more
Source: ClinicalTrials.gov public record
Updated Aug 10, 2020 · Synced Sep 11, 2026, 4:05 PM EDT
Terminated Phase 2 Interventional

Interferon-alpha Treatment of Chronic Cough in Chronic Obstructive Pulmonary Disease and Idiopathic Pulmonary Fibrosis

NCT00690885
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive, Pulmonary Fibrosis, Cough
Interventions
interferon-alpha lozenges, placebo lozenges
Drug
Lead sponsor
Ainos, Inc. (f/k/a Amarillo Biosciences Inc.
Industry
Eligibility
40 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
1
States / cities
Lubbock, Texas
Source: ClinicalTrials.gov public record
Updated Apr 23, 2012 · Synced Sep 11, 2026, 4:05 PM EDT
Approved For Marketing No phase listed Expanded access

Expanded Access Program of Nintedanib in Patients With Idiopathic Pulmonary Fibrosis (EAP)

NCT02171156
View directory record Official record
Conditions
Idiopathic Pulmonary Fibrosis
Interventions
nintedanib
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
40 Years and older
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
7
States / cities
Winter Park, Florida • Skokie, Illinois • Muncie, Indiana + 4 more
Source: ClinicalTrials.gov public record
Updated May 7, 2017 · Synced Sep 11, 2026, 4:05 PM EDT
Completed No phase listed Observational

Beneficial Effects of Pulmonary Rehabilitation for Idiopathic Pulmonary Fibrosis

NCT01107028
View directory record Official record
Conditions
Idiopathic Pulmonary Fibrosis
Interventions
Standard pulmonary rehabilitation program
Other
Lead sponsor
National Jewish Health
Other
Eligibility
40 Years and older
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
1
States / cities
Denver, Colorado
Source: ClinicalTrials.gov public record
Updated Oct 21, 2020 · Synced Sep 11, 2026, 4:05 PM EDT
Completed Phase 2 Interventional

A Study to Evaluate the Safety and Effectiveness of CNTO 888 Administered Intravenously (IV) in Participants With Idiopathic Pulmonary Fibrosis (IPF)

NCT00786201
View directory record Official record
Conditions
Pulmonary Fibrosis
Interventions
Placebo, CNTO 888 1 mg/kg, CNTO 888 5 mg/kg, CNTO 888 15 mg/kg
Drug
Lead sponsor
Centocor, Inc.
Industry
Eligibility
40 Years to 80 Years
Enrollment
126 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
17
States / cities
Birmingham, Alabama • Phoenix, Arizona • Miami, Florida + 14 more
Source: ClinicalTrials.gov public record
Updated Dec 27, 2015 · Synced Sep 11, 2026, 4:05 PM EDT
Completed Phase 2 Interventional

Treatment of Idiopathic Pulmonary Fibrosis With Thalidomide

NCT00162760
View directory record Official record
Conditions
Idiopathic Pulmonary Fibrosis (IPF)
Interventions
Thalidomide
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
50 Years to 80 Years
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2007
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 21, 2010 · Synced Sep 11, 2026, 4:05 PM EDT
Terminated Phase 2 Interventional Results available

Study of Pharmacodynamics, Pharmacokinetics, Safety and Tolerability of VAY736 in Patients With Idiopathic Pulmonary Fibrosis

NCT03287414
View directory record Official record
Conditions
Idiopathic Pulmonary Fibrosis
Interventions
VAY736, Placebo, Standard of Care (SoC)
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
40 Years to 80 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
7
States / cities
Birmingham, Alabama • Aurora, Colorado • Miami, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Jun 17, 2024 · Synced Sep 11, 2026, 4:05 PM EDT
Completed Phase 2 Interventional

A Study of the Safety and Clinical Effects of Interferon Gamma-1b in Patients With Idiopathic Pulmonary Fibrosis (IPF)

NCT00047658
View directory record Official record
Conditions
Idiopathic Pulmonary Fibrosis
Interventions
Interferon-gamma 1b
Drug
Lead sponsor
InterMune
Industry
Eligibility
20 Years to 79 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2003
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Nov 5, 2007 · Synced Sep 11, 2026, 4:05 PM EDT
Recruiting Phase 2 Interventional

A Phase IIb Study to Evaluate AZD8965 in Participants With IPF.

NCT07652658
View directory record Official record
Conditions
Idiopathic Pulmonary Fibrosis (IPF)
Interventions
Placebo for AZD8965, AZD8965 low dose, AZD8965 medium dose, AZD8965 high dose
Other · Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
40 Years and older
Enrollment
359 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
36
States / cities
Birmingham, Alabama • Phoenix, Arizona • Loma Linda, California + 30 more
Source: ClinicalTrials.gov public record
Updated Jun 24, 2026 · Synced Sep 11, 2026, 4:05 PM EDT
Not listed Early Phase 1 Interventional

Use of cSVF Via IV Deployment for Residual Lung Damage After Symptomatic COVID-19 Infection

NCT04326036
View directory record Official record
Conditions
Pulmonary Alveolar Proteinosis, COPD, Idiopathic Pulmonary Fibrosis, Viral Pneumonia, Coronavirus Infection, Interstitial Lung Disease
Interventions
Microcannula Harvest Adipose Derived tissue stromal vascular fraction (tSVF), Centricyte 1000, IV Deployment Of cSVF In Sterile Normal Saline IV Solution, Liberase Enzyme (Roche), Sterile Normal Saline for Intravenous Use
Procedure · Device · Drug
Lead sponsor
Black Tie Medical, Inc.
Industry
Eligibility
18 Years to 90 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
1
States / cities
Stevensville, Montana
Source: ClinicalTrials.gov public record
Updated Feb 21, 2023 · Synced Sep 11, 2026, 4:05 PM EDT
Not listed No phase listed Observational

Patient-Reported Outcome Study of Project ECHO for ILD

NCT05450276
View directory record Official record
Conditions
Interstitial Lung Disease
Interventions
Not listed
Lead sponsor
Pulmonary Care and Research Collaborative Limited
Other
Eligibility
18 Years and older
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 7, 2022 · Synced Sep 11, 2026, 4:05 PM EDT
Terminated Phase 2 Interventional

A Study to Characterize the Safety, PK and Biological Activity of CC-930 in Idiopathic Pulmonary Fibrosis (IPF)

NCT01203943
View directory record Official record
Conditions
Idiopathic Pulmonary Fibrosis, Pulmonary Fibrosis, Fibrosis, Interstitial Lung Disease, Lung Diseases, Interstitial
Interventions
CC-930, Placebo
Drug · Other
Lead sponsor
Celgene
Industry
Eligibility
50 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
16
States / cities
Birmingham, Alabama • Sacramento, California • Stanford, California + 13 more
Source: ClinicalTrials.gov public record
Updated Nov 18, 2019 · Synced Sep 11, 2026, 4:05 PM EDT
Recruiting Phase 2 Interventional

Zinc and Nicotinamide Riboside for Idiopathic Pulmonary Fibrosis

NCT06567717
View directory record Official record
Conditions
Idiopathic Pulmonary Fibrosis
Interventions
Zinc, Placebos for zinc and nicotinamide riboside, Nicotinamide riboside
Drug · Other
Lead sponsor
Cedars-Sinai Medical Center
Other
Eligibility
50 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Nov 9, 2025 · Synced Sep 11, 2026, 4:05 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Using MRI to Visualize Regional Therapy Response in Idiopathic Pulmonary Fibrosis

NCT02478268
View directory record Official record
Conditions
Idiopathic Pulmonary Fibrosis
Interventions
Hyperpolarized 129-Xenon gas, MRI
Drug · Device
Lead sponsor
Bastiaan Driehuys
Other
Eligibility
18 Years and older
Enrollment
64 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2020
U.S. locations
2
States / cities
Durham, North Carolina • Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Oct 10, 2021 · Synced Sep 11, 2026, 4:05 PM EDT
Completed Phase 1Phase 2 Interventional

Safety Study of Tetrathiomolybdate in Patients With Idiopathic Pulmonary Fibrosis

NCT00189176
View directory record Official record
Conditions
Idiopathic Pulmonary Fibrosis
Interventions
Tetrathiomolybdate
Drug
Lead sponsor
University of Michigan
Other
Eligibility
35 Years to 80 Years
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2006
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Feb 5, 2013 · Synced Sep 11, 2026, 4:05 PM EDT
Terminated Phase 2Phase 3 Interventional Results available

Targeting Vascular Reactivity in Idiopathic Pulmonary Fibrosis

NCT00981747
View directory record Official record
Conditions
Idiopathic Pulmonary Fibrosis, Pulmonary Fibrosis
Interventions
Sildenafil, Losartan, Sildenafil and Losartan, Placebo Oral Tablet
Drug
Lead sponsor
Alicia Gerke
Other
Eligibility
18 Years to 99 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2016
U.S. locations
1
States / cities
Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated Nov 12, 2018 · Synced Sep 11, 2026, 4:05 PM EDT
Recruiting Phase 2 Interventional

Study of ABBV-142 to Assess Adverse Events and Change in Disease Activity in Adult Participants With Idiopathic Pulmonary Fibrosis

NCT07230288
View directory record Official record
Conditions
Idiopathic Pulmonary Fibrosis
Interventions
ABBV-142, Placebo for ABBV-142
Drug
Lead sponsor
AbbVie
Industry
Eligibility
40 Years and older
Enrollment
165 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
10
States / cities
Birmingham, Alabama • Dothan, Alabama • Kissimmee, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Sep 2, 2026 · Synced Sep 11, 2026, 4:05 PM EDT
Completed No phase listed Observational

Race, Ethnicity, and Diffuse Parenchymal Lung Disease

NCT00453713
View directory record Official record
Conditions
Idiopathic Pulmonary Fibrosis, Interstitial Lung Disease, Diffuse Parenchymal Lung Disease
Interventions
Not listed
Lead sponsor
Columbia University
Other
Eligibility
18 Years and older
Enrollment
565 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2013
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 20, 2015 · Synced Sep 11, 2026, 4:05 PM EDT
Completed Phase 2 Interventional

Safety, Tolerability, and Efficacy Study of Idiopathic Pulmonary Fibrosis

NCT01262001
View directory record Official record
Conditions
Idiopathic Pulmonary Fibrosis
Interventions
FG-3019
Drug
Lead sponsor
Kyntra Bio
Industry
Eligibility
35 Years to 80 Years
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2017
U.S. locations
18
States / cities
Birmingham, Alabama • Scottsdale, Arizona • New Haven, Connecticut + 15 more
Source: ClinicalTrials.gov public record
Updated Oct 8, 2019 · Synced Sep 11, 2026, 4:05 PM EDT
Recruiting Phase 1 Interventional

Molecular Imaging Probes to Inform Heterogeneity in Idiopathic Pulmonary Fibrosis

NCT04362644
View directory record Official record
Conditions
Idiopathic Pulmonary Fibrosis
Interventions
PET/CT using PET ligands [F-18]FDG and [F-18]DPA-714
Drug
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
40 Years to 85 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Aug 11, 2026 · Synced Sep 11, 2026, 4:05 PM EDT